10 August 2017

Contents

Special reports

• i-Base 2017 appeal: we need your help….

Conference reports

• 9th IAS Conference on HIV Science (IAS 2017)

• HIV pipeline drugs: IAS 2017 update

• Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

• Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

• Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

• Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

• Reduced-dose darunavir is safe and effective in switch study

• MK-8591: further compelling early results for both treatment and prevention

• Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

• Preliminary results on dolutegravir use in pregnancy are reassuring

• Low dose efavirenz (EFV400) can be used during pregnancy

• Stillbirth rate in HIV positive women in UK/Ireland is double that of the general population

• Swaziland nearly halves HIV incidence in five years

• Gay men with undetectable viral load do not transmit HIV: Opposites Attract study supports U=U

• HIV remission news from IAS 2017

• Publications launched at IAS 2017

• 9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris

• Chewable raltegravir tablets can be crushed and dispersed in liquid for young children

• Inconsistencies between real-world data from UK and Ireland and EU recommendations for new antiretrovirals in pregnancy

Antiretrovirals

• First dolutegravir-based generic FDC gets FDA tentative approval

• FDA grant priority review for ibalizumab

Hepatitis coinfection

• UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’

HIV prevention and transmission

• Controversial PrEP study from NHS England due to start in September

PDFs

• July/August 2017: Volume 18 Number 7/8